MARKET

AVDL

AVDL

Avadel
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.73
-0.02
-0.23%
Opening 13:27 02/24 EST
OPEN
8.89
PREV CLOSE
8.75
HIGH
9.09
LOW
8.61
VOLUME
209.37K
TURNOVER
--
52 WEEK HIGH
13.49
52 WEEK LOW
4.000
MARKET CAP
508.27M
P/E (TTM)
-114.8684
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Avadel Pharmaceuticals to Provide a Company Update and Report Fourth Quarter and Full Year 2020 Financial Results, on March 9th
DUBLIN, Ireland, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy...
GlobeNewswire · 19h ago
Global Rabeprazole Market 2020 Regulatory Framework, Market Strategies and End-User Applicants by 2025
Feb 22, 2021 (CDN Newswire via Comtex) -- The most recent report namely Global Rabeprazole Market 2020 by Manufacturers, Type and Application, Forecast to...
CDN Newswire · 1d ago
Avadel Pharmaceuticals names new Chief Commercial Officer
Avadel Pharmaceuticals (AVDL) appointed 25-years industry veteran Richard Kim to the newly formed role of Chief Commercial Officer for leading all aspects of the U.S. commercial launch of the company’s lead program, once-nightly FT218, pending
Seekingalpha · 02/17 13:53
8-K: AVADEL PHARMACEUTICALS PLC
(EDGAR Online via COMTEX) -- 0001012477 false 0001012477 2021-02-15 2021-02-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/17 13:13
Avadel Pharmaceuticals Appoints Richard Kim As CCO; Says He Will Lead Launch Of Once-Nightly FT218, Pending Regulatory Approval
Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218 DUBLIN, Ireland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals
Benzinga · 02/17 13:06
Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial Officer to Lead the Commercial Launch of Once-Nightly FT218
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy, today announced the app...
GlobeNewswire · 02/17 13:00
Avadel Pharmaceuticals to Participate in a Fireside Chat at the 10th Annual SVB Leerink Global Healthcare Conference
DUBLIN, Ireland, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in a...
GlobeNewswire · 02/10 13:00
Myasthenia Gravis Treatment Market Share,Size 2021 – Global Trends, Market Demand, Industry Analysis, Growth, Opportunities and Forecast 2025
The Express Wire · 02/10 08:36
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVDL. Analyze the recent business situations of Avadel through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVDL stock price target is 18.33 with a high estimate of 23.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 142
Institutional Holdings: 46.93M
% Owned: 80.61%
Shares Outstanding: 58.22M
TypeInstitutionsShares
Increased
21
1.82M
New
40
2.94M
Decreased
21
1.29M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.43%
Pharmaceuticals & Medical Research
+1.32%
Key Executives
Non-Executive Chairman/Independent Director
Geoffrey Glass
Chief Executive Officer/Chief Operating Officer/Executive Vice President/Director
Gregory Divis
Chief Financial Officer
Thomas McHugh
Other
Richard Kim
Independent Director
Eric Ende
Independent Director
Mark McCamish
Independent Director
Linda Palczuk
Independent Director
Peter Thornton
  • Dividends
  • Splits
  • Insider Activity
No Data
About AVDL
Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

Webull offers kinds of Avadel Pharmaceuticals PLC (ADR) stock information, including NASDAQ:AVDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVDL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVDL stock methods without spending real money on the virtual paper trading platform.